Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
1563
resultados
Última actualización
19/12/2025 [07:14:00]
Resultados 325 a 350 de 1563
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: JP2025098004A
To provide methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC).SOLUTION: The present invention provides a method comprising administering to the patient an agonist of the Macrophage Stimulating 1 (MST1)/Macrophage Stimulating 1 Receptor (MST1R) pathway.SELECTED DRAWING: None
Resumen de: WO2025226885A1
The present invention relates to a biomarker associated with intestinal inflammation, and more particularly, to methods for diagnosing or identifying a risk of developing intestinal inflammation using mitochondrial DNA and methods of treating disorders associated with intestinal inflammation.
Resumen de: US2025334593A1
In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
Resumen de: US2025332230A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: WO2025224462A1
The invention relates to DNA methylation and gene expression signatures for assessing the severity of IBD in a patient, monitoring the progression of IBD in a patient, and/or determining the efficacy of a therapeutic agent for treating IBD in a patient. The DNA methylation and gene expression signatures of the invention can also be used for the differential diagnosis of Crohn's Disease or Ulcerative Colitis in a patient having or suspected of having IBD. The invention further relates to intestinal epithelial organoids (IEOs) for predicting the efficacy of therapeutic agents and for screening agents for use in treating IBD. The invention further relates to therapeutic agents for use in treating IBD.
Resumen de: WO2024130444A1
The present application provides compositions and methods of use for inhibiting DUPD1 activity or by reducing or eliminating expression of DUPD1 in order to treat and/or prevent inflammatory bowel disease, including Crohn's disease and ulcerative colitis, colitis- associated colon cancer, or a metabolic disorder, such as obesity or an obesity-associated metabolic disorder, or for glucose regulation in a subject. The present application further relates to the identification of compounds that are useful in treating and/or preventing inflammatory bowel disease, colitis-associated colon cancer, or a metabolic disorder, or for glucose regulation.
Resumen de: CN120831477A
The invention discloses a novel target of PPP2R1A as an anti-inflammatory therapeutic drug and application of the novel target, it is found for the first time that knock-down of PPP2R1A can significantly inhibit expression of an anti-inflammatory active compound PB in NF-kB, TNF-alpha and IL-1beta inflammatory factors in human colon tumor cells, and at present, the relationship between PPP2R1A protein and inflammation has not been researched. The invention provides a novel drug target for treatment of inflammatory diseases in the field, provides a practical and effective screening method for discovery of inflammation treatment leading drugs, provides a scientific basis for clinical treatment of ulcerative colitis, and has a good application prospect in the aspect of anti-inflammation.
Resumen de: WO2025218823A2
Disclosed in the present invention are a joint detection kit for detecting intestinal polyp factors, and a preparation method therefor, a detection method therefor and the use thereof. The joint detection kit at least comprises a plurality of test strips for detecting the following indicators: M2-pyruvate kinase, matrix metalloproteinase 9, myeloperoxidase, glutathione S-transferase Pi, cytidine deaminase, retinol binding protein 4, serine protease inhibitor F2, calprotectin and fecal occult blood. Conjugate pads of each reagent strip are coated with detection antibody-colloidal gold conjugates. Detection lines of the reagent strip are coated with specific capture antibodies, and the specific capture antibodies on each test strip are different. The joint detection performed by the joint detection kit of the present invention can effectively improve the sensitivity and specificity of the detection on intestinal polyps. The detection time is merely 15 min, with the detection rate of more than 91%. Therefore, the accuracy on the detection and diagnosis of colorectal cancer caused by intestinal polyps is improved.
Resumen de: CN120820665A
The invention discloses a biomarker for identifying superior mesenteric artery dissection related intestinal dysfunction. The biomarker is lysophospholipid. By means of the biomarker, a patient with intestinal dysfunction caused by SISMAD can be recognized in an early stage, operation intervention (mainly stent implantation) can be conducted in time, and malignant consequences such as intestinal necrosis, large-area intestinal resection, short bowel syndrome and infection death are avoided.
Resumen de: CN120818614A
The invention discloses a microbial marker for treating Crohn's disease based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dialister insight, Roseburia intestinae, Parabacteroides verdeae, Bacteroides caccae, Blauria obeum, Bacteroides intestinae, Paraprevotella, and a combination of the Bacteroides cactinae, and further comprises the following components in parts by weight: 1, 1, 2, 3, 4, 5, 6, 7, 7, 8, 8, 8, 9, 10, 12, 13, 13, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17 According to the invention, through metagenome sequencing and a machine learning algorithm, the key microbial marker which is significantly related to the symptom improvement of the Crohn's disease in the coprophilous fungus transplantation treatment process is screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of the Crohn's disease.
Resumen de: CN120789208A
The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ulcerative colitis as well as a preparation method and application thereof. The invention discloses a traditional Chinese medicine composition for treating ulcerative colitis. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-60 parts of codonopsis pilosula, 10-50 parts of roasted rhizoma atractylodis macrocephalae, 10-50 parts of roasted radix aucklandiae, 10-50 parts of parched white peony root, 10-50 parts of rhizoma cimicifugae, 10-50 parts of bran-fried Chinese yam, 10-50 parts of myristica fragrans, 20-40 parts of vinegar smoked plum, 10-30 parts of fried fructus chebulae, 10-30 parts of baked ginger and 5-45 parts of honey-fried licorice root. According to the traditional Chinese medicine composition provided by the invention, the level of a proinflammatory marker is remarkably reduced, the balance of M1/M2 macrophages in colon tissues is regulated, the damage of oxidative stress to the colon mucosal barrier can be effectively reversed, and the expression of a PI3K/AKT/mTOR signal channel and HIF-1alpha is regulated, so that the curative effects of relieving inflammatory response and accelerating repair are achieved.
Resumen de: CN120796172A
The invention relates to the technical field of bioengineering, and discloses a construction method of an inflammatory bowel disease model, which comprises the following steps: constructing an inflammatory intestinal barrier by using intestinal cells derived from an inflammatory bowel disease patient; and S20, adding a stimulation solution containing immune cells and/or immune cell secretions into the inflammatory intestinal barrier, and carrying out co-culture to obtain the inflammatory bowel disease model. An inflammatory intestinal barrier constructed by using intestinal cells derived from an inflammatory bowel disease patient and adding immune components can retain IBD disease-related gene and cell shape feature expression characteristics, so that the model is closer to the pathological condition in the body of the patient; and moreover, the actual in-vivo pathological injury progress is better simulated, the bionic property of the model is improved, the injury of unbalanced immune cells to the intestinal tract in IBD pathology is reproduced, and potential drug targets can be found and verified. The invention further discloses an inflammatory bowel disease model and application thereof.
Resumen de: US2025321218A1
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.
Resumen de: US2025319052A1
This present invention relates to the use of eicosapentaenoic acid (EPA) for the treatment of ulcerative colitis (UC), and more particularly, the use of highly purified eicosapentaenoic acid as free fatty acids (EPA-FFA) having a purity of at least 95% for reducing inflammation in a subject suffering from ulcerative colitis and wherein the levels of IL-10 and SOCS3 are increased and the microbiome of the intestinal mucosal tissue is favorably modulated.
Resumen de: EP4632080A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: CN120775993A
The invention belongs to the field of molecular genetics, and particularly relates to an SNP (Single Nucleotide Polymorphism) molecular marker combination for genetic relationship identification of wuzhu cattle and application of the SNP molecular marker combination. The SNP marker combination is composed of 140 high-polymorphism SNP sites distributed on a plurality of chromosomes of a bovine whole genome, the average distance between the sites is reasonable, and the SNP marker combination has good genome coverage. The selected SNP site has high allele frequency (MAF), expected heterozygosity (He) and polymorphic information content (PIC), and the cumulative exclusion probability is 0.9999. King and Plink software are combined to deduce a genetic relationship coefficient (Kinship) and an IBD shared value (PIHAT) between samples, and a result shows that the marker combination can realize a genetic relationship recognition effect equivalent to that of whole genome SNP data in Wuzhu white cattle (grassland white cattle), and the scientificity and practicability of the marker combination are verified. The SNP molecular marker combination can be widely applied to the processes of germplasm resource management, pedigree correction and cattle breeding, and has good popularization prospects and economic benefits.
Resumen de: KR20250148382A
본 발명은 염증성 장질환(inflammatory bowel disease, IBD) 진단 및 치료를 위한 miRNA 바이오마커를 제공한다. 본 발명의 일 실시예에 따른 바이오마커는 염증성 장질환 진단용 조성물, 진단을 위한 정보 제공 방법, 염증성 장질환 예방 또는 치료용 약학 조성물, 염증성 장질환을 치료하는 방법 및 염증성 장질환 치료제의 스크리닝 방법에 활용될 수 있다.
Resumen de: CN120758646A
The invention discloses a tetraploid crassostrea gigas parent-child relationship identification method based on SNP sites, and belongs to the technical field of tetraploid crassostrea gigas molecular assisted breeding. The method for identifying the parent-child relationship of tetraploid crassostrea gigas comprises the following steps: (1) sequencing adductor muscles of tetraploid crassostrea gigas to be detected; (2) comparing the reference genome of the crassostrea gigas to obtain the genotype of the specified SNP site of the tetraploid crassostrea gigas; (3) calculating IBS and LOD of the to-be-detected parents and the to-be-detected offspring according to an SNP typing result; and (4) identifying the parent-child relationship between the to-be-detected parent and the filial generation by combining IBS and LOD. The SNP loci have the advantages that 1000 SNP loci for identifying the parent-child relationship of the tetraploid crassostrea gigas are disclosed for the first time, data support is provided for identifying the parent-child relationship of the tetraploid crassostrea gigas, a foundation is laid for developing a liquid phase chip for identifying the parent-child relationship of the tetraploid crassostrea gigas, and the SNP loci have good application prospects.
Resumen de: US2025313880A1
Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: US2025313613A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: WO2025210486A1
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.
Nº publicación: US2025304705A1 02/10/2025
Solicitante:
UNIV OF UTAH RESEARCH FOUNDATION [US]
UNIVERSITY OF UTAH RESEARCH FOUNDATION
Resumen de: US2025304705A1
The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
BOPI
Sede Electrónica
